Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841 · View on ClinicalTrials.gov ↗
Study Summary
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Pomalidomide
- DRUG Carfilzomib
- DRUG Elotuzumab
- DRUG Etentamig
Study Locations (20)
California
- Alta Bates Summit Medical Center for Research /ID# 261438 — Berkeley
- Providence - St. Jude Medical Center /ID# 262031 — Fullerton
- VA Loma Linda Healthcare System /ID# 261015 — Loma Linda
- Cedars-Sinai Medical Center /ID# 261008 — Los Angeles
Illinois
- University of Illinois Hospital and Health Sciences System /ID# 246349 — Chicago
- Rush University Medical Center /ID# 265690 — Chicago
- Nancy W. Knowles Cancer Center /ID# 271361 — Elmhurst
- Springfield Clinic - First /ID# 262266 — Springfield
Florida
- Mayo Clinic Hospital Jacksonville /ID# 263324 — Jacksonville
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 — Jacksonville
Massachusetts
- Beth Israel Deaconess Medical Center /ID# 271535 — Boston
- Dana-Farber Cancer Institute /ID# 261554 — Boston
Michigan
- Regents of the University of Michigan /ID# 261577 — Ann Arbor
- Karmanos Cancer Institute - Detroit /ID# 266298 — Detroit
Alabama
- University of Alabama at Birmingham - Main /ID# 261434 — Birmingham
Arizona
- Mayo Clinic Hospital - Phoenix /ID# 263326 — Phoenix
Colorado
- Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 — Lone Tree
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2024-05-19 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06158841
The ClinicalTrials.gov registry entry for NCT06158841 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions — of which Selinexor is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06158841 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06158841 about?
NCT06158841 is a clinical study titled "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma". Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed...
What is the current status of trial NCT06158841?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2024-05-19. Estimated completion is 2027-12.
What conditions does trial NCT06158841 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06158841?
The interventions under investigation include: Selinexor (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG), Elotuzumab (DRUG), Etentamig (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06158841?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06158841 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.